Latest news with #IntegratedStressResponse
Yahoo
25-04-2025
- Business
- Yahoo
Bantam Pharmaceutical Presents New Preclinical Data for BTM-3566 at the American Association for Cancer Research (AACR) Annual Meeting 2025
• BTM-3566 shows solid tumor regression and identifies FAM210B as a potential biomarker for response and combination strategies RESEARCH TRIANGLE PARK, N.C., April 25, 2025 /PRNewswire/ -- Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, today announced solid tumor regression data from Bantam's lead product candidate, BTM-3566. These preclinical data will be shared in a poster presentation during the American Association for Cancer Research (AACR) Annual Meeting, being held from April 25-30, 2025 at the McCormick Place Convention Center in Chicago, Illinois. The poster highlights evidence of robust anti-tumor activity in a broad range of solid tumor models, as well as introduces FAM210B, a mitochondrial protein, as a potential biomarker for response. BTM-3566 is a first-in-class, small molecule cancer therapeutic which targets difficult-to-treat, aggressive tumors by activating OMA1-ATF4 Integrated Stress Response (ISR), a newly described mitochondrial homeostasis pathway. Previously, BTM-3566 was shown to have strong single-agent activity in both cell line and patient-derived xenograft (PDX) models of mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL), regardless of cell of origin (COO) or genotype. The new data extend these findings to solid tumors and demonstrate that BTM-3566 has in vitro and in vivo activity across tumor types. Key findings include: BTM-3566 exhibits in vitro and in vivo activity in a broad range of solid tumor models BTM-3566 drives tumor regression in models with low FAM210B RNA expression, supporting the use of FAM210B as a potential biomarker for response Ectopic expression of FAM210B blocks drug activity in multiple models, suggesting a mechanistic role for the protein in mediating response BTM-3566 demonstrates additive and synergistic activity in combination with other agents from multiple classes in preclinical models, including BH3 mimetics, supporting future combination strategies "These findings provide important insight into the unique mechanism of our lead compound and support the potential for future patient selection using FAM210B expression," said Michael Stocum, President & CEO of Bantam Pharmaceutical. "We believe BTM-3566 holds promise not only as a monotherapy but also in combination with numerous approved anti-cancer agents, potentially expanding treatment options for patients with aggressive, hard-to-treat tumors. We intend to further explore these relationships as product development progresses." Poster Presentation Details Title: Selective pharmacological activation of the mitochondrial protease OMA1 inhibits tumor growth and induces regression in tumors expressing low levels of FAM210BPresenter: Matthew Kostura, PhD, Chief Scientific Officer, Bantam PharmaceuticalSession: Experimental and Molecular TherapeuticsDate/Time: Monday, April 28th at 3 p.m. to 6 p.m. ETAbstract Number: 3032 The poster presentation will be available under the News & Resources section of the company's website shortly after the event. About BTM-3566 BTM-3566 is a novel, orally available small molecule designed to target a wide range of cancers, including both hematologic and solid tumors. Its initial clinical focus is on mature B-cell lymphomas, such as mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL). In preclinical studies, BTM-3566 demonstrated potent anti-cancer activity, driving significant tumor regression – and in many cases, complete tumor elimination – in models resistant to standard treatments, including CAR-T cell therapy. BTM-3566 works by disrupting the mitochondrial function in tumor cells, triggering their natural cell death process (apoptosis). With its unique mechanism of action and strong preclinical data, Bantam also plans to expand clinical development into solid tumors, broadening its potential impact for patients with limited treatment options. Currently, Bantam is conducting an ongoing Phase 1 clinical trial in both the U.S. and Canada evaluating BTM-3566 in relapsed/refractory mature B-cell lymphomas. For more information about the U.S. trial, visit and search NCT06792734. About Bantam Pharmaceutical Bantam Pharmaceutical is a drug discovery and development company leveraging the power of mitochondrial dynamics to address critical unmet needs in oncology. Using its unique expertise in mitochondrial cellular biology, Bantam is advancing novel, first-in-class oral small molecule therapeutics for difficult-to-treat hematological and solid tumors. The company currently holds an active Investigational New Drug (IND) application in the U.S. and a Clinical Trial Application (CTA) in Canada for its lead candidate, BTM-3566, targeting B-cell malignancies, with plans to expand clinical development into solid tumors. Learn more at Media Contact Jennifer AlmondCorporate CommunicationsBantam Pharmaceuticaljalmond@ View original content to download multimedia: SOURCE Bantam Pharmaceutical, LLC Sign in to access your portfolio
Associated Press
26-03-2025
- Business
- Associated Press
Bantam Pharmaceutical to Present at the American Association for Cancer Research (AACR) Annual Meeting 2025
RESEARCH TRIANGLE PARK, N.C., March 26, 2025 /PRNewswire/ -- Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, today announced that its abstract has been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting, which is being held April 25-30, 2025 at the McCormick Place Convention Center in Chicago, Illinois. The poster presentation will highlight solid tumor regression data from Bantam's lead product candidate, BTM-3566. BTM-3566 is a first-in-class, small molecule cancer therapeutic which targets difficult-to-treat aggressive tumors by activating the OMA1-ATF4 Integrated Stress Response (ISR), a newly described mitochondrial homeostasis pathway. Leveraging its unique mechanism of action, BTM-3566 demonstrated robust activity as a single agent in vivo in solid tumors with low FAM210B RNA expression. Additionally, preclinical data suggest that rational combinations with BH3 mimetics could extend the therapeutic potential of BTM-3566, particularly in difficult-to-treat tumors. Poster Presentation Details Title: Selective pharmacological activation of the mitochondrial protease OMA1 inhibits tumor growth and induces regression in tumors expressing low levels of FAM210B Presenter: Matthew Kostura, PhD, Chief Scientific Officer, Bantam Pharmaceutical Session: Experimental and Molecular Therapeutics Date/Time: Monday, April 28th at 3 p.m. to 6 p.m. ET Abstract Number: 3032 Additional meeting information can be found on the AACR website, The poster presentation will be made available under the News & Resources section of the company's website shortly after the event. About BTM-3566 BTM-3566 is a novel, orally available small molecule designed to target a wide range of cancers, including both hematologic and solid tumors. Its initial clinical focus is on mature B-cell lymphomas, such as mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL). In preclinical studies, BTM-3566 demonstrated potent anti-cancer activity, driving significant tumor regression – and in many cases, complete tumor elimination – in models resistant to standard treatments, including CAR-T cell therapy. BTM-3566 works by disrupting the mitochondrial function in tumor cells, triggering their natural cell death process (apoptosis). With its unique mechanism of action and strong preclinical data, Bantam also plans to expand clinical development into solid tumors, broadening its potential impact for patients with limited treatment options. Currently, Bantam is conducting an ongoing Phase 1 clinical trial in both the U.S. and Canada evaluating BTM-3566 in relapsed/refractory mature B-cell lymphomas. For more information about the U.S. trial, visit and search NCT06792734. About Bantam Pharmaceutical Bantam Pharmaceutical is a drug discovery and development company leveraging the power of mitochondrial dynamics to address critical unmet needs in oncology. Using its unique expertise in mitochondrial cellular biology, Bantam is advancing novel, first-in-class oral small molecule therapeutics for difficult-to-treat hematological and solid tumors. The company currently holds an active Investigational New Drug (IND) application in the U.S. and a Clinical Trial Application (CTA) in Canada for its lead candidate, BTM-3566, targeting B-cell malignancies, with plans to expand clinical development into solid tumors. Learn more at Media Contact Jennifer Almond
Associated Press
06-02-2025
- Business
- Associated Press
InFlectis BioScience Announces Promising Results for IFB-088 in a Phase 2a Clinical Study in Bulbar-Onset ALS Patients
Nantes, France--(Newsfile Corp. - February 6, 2025) - InFlectis BioScience SAS, a drug discovery company pioneering development of therapeutics harnessing the Integrated Stress Response (ISR) for a spectrum of neurological diseases, today announced the successful completion of its P288ALS TRIAL study (NCT05508074). This study was designed as a randomized, double-blind, placebo-controlled, parallel-group phase 2a trial comparing its drug candidate IFB-088 (25 mg BID) plus riluzole with placebo plus riluzole, in patients afflicted with bulbar-onset ALS, a particularly severe ALS subtype. To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: Promising results reported for IFB-088 in a Phase 2a clinical study in bulbar-onset ALS Patients. Biomarker evidence highlights IFB-088 impact on integrated stress response and oxidative pathways. These findings confirm the hypotheses raised from preclinical studies and strongly support the premise of moving IFB-088 to pivotal study. [ This image cannot be displayed. Please visit the source: ] Click image above to view full announcement. About IFB-088 (icerguastat) InFlectis is developing IFB-088 (also named sephin1), a first-in-class, multi-functional, brain-penetrant, orally administered small molecule that selectively inhibits the dephosphorylation of eIF2. By doing so, IFB-088 amplifies the integrated stress response (ISR), acting as a formidable shield against various cellular stresses, including endoplasmic reticulum (ER) stress which is a hallmark of neurodegeneration. IFB-088 also selectively antagonizes NMDA receptors containing the NR2B subunit, which are involved in glutamate excitotoxicity that triggers calcium influx, mitochondrial dysfunction, and ROS production, and ultimately contributes to neurodegeneration. IFB-088 also reduces mitochondrial ROS production in an NMDAR-independent manner. Hence, IFB-088 normalizes dysregulated calcium homeostasis and oxidative stress to provide neuroprotection in different diseases context. This approach holds promise for designing disease-modifying therapeutics to fight intractable diseases such as ALS. About Bulbar-Onset ALS ALS is increasingly being recognized as a heterogeneous disease. To optimize assessment in a small study, InFlectis has focused IFB-088 development to date on bulbar-onset ALS patients, who account for ~30% of all ALS patients and represent a more homogeneous patient population. Bulbar ALS is a distinct phenotype identified with specific clinical parameters; disease onset primarily affects the brainstem, impacting muscles responsible for speech, swallowing, and limb functions. Patients experience slurred speech (dysarthria) and difficulty swallowing (dysphagia) early in the disease progression. Bulbar-onset ALS usually exhibits a rapid evolution and poor prognosis (~26 months from symptom onset to death). Treatment options remain a high unmet medical need for this patient group. About the ALS ASSOCIATION The ALS Association is the largest philanthropic funder of ALS research in the world. The Association funds global research collaborations, assists people with ALS and their families through its nationwide network of care and certified clinical care centers, and advocates for better public policies for people with ALS. The ALS Association is working to make ALS a livable disease while urgently searching for new treatments and a cure. For more information about the ALS Association, visit our website at About AFM-T'el'ethon The French Muscular Dystrophy Association (AFM) - AFM-Telethon - is a major player in biomedical research for rare diseases in France and worldwide. It currently funds about 350 research programs and 40 clinical trials in different genetic diseases affecting the eye, blood, brain, immune system, motor neurons and muscles... The AFM-Telethon has also created three research and development institutes dedicated to gene therapy, stem cells and myology. To learn more visit Contacts: Pierre Miniou
